PDE4A and chronic obstructive pulmonary disease: In light of these limitations, only one oral PDE4 inhibitor (namely roflumilast) is at present commercially available for use in COPD (Giembycz and Field, 2010), a pathology where at variance with asthma, ICS cannot effectively control airway phlogosis.